.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,585,370

« Back to Dashboard

Details for Patent: 5,585,370

Title: Hormone preparation and method
Abstract:This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.
Inventor(s): Casper; Robert F. (Toronto, CA)
Assignee: Jencap Research Ltd. (Toronto, CA)
Filing Date:Dec 05, 1994
Application Number:08/354,004
Claims:1. A contraceptive preparation for administration to a female of childbearing capability comprising repeating cycles of a contraceptive regimen, each cycle having a series of twenty to thirty-five consecutive daily unit doses arranged in alternating estrogen dominant phases and progestin dominant phases, each phase consisting of from two to four consecutive daily unit doses, wherein the daily unit doses of said estrogen dominant phases contain i) an amount of a substance exhibiting estrogen activity or ii) an amount of a substance exhibiting estrogen activity and an amount of a substance exhibiting progestin activity, and the daily unit doses of said progestin dominant phases contain an amount of a substance exhibiting estrogen activity and an amount of a substance exhibiting progestin activity; wherein the amount of said substance exhibiting progestin activity is alternately increased in the progestin dominant phases to provide daily unit doses exhibiting progestin dominant activity and decreased in the estrogen dominant phases to provide daily unit doses exhibiting estrogen dominant activity, and wherein the amount of substance exhibiting estrogen activity per unit dose exhibits an estrogen activity equivalent to from about 0.02 to about 0.05 mg of 17.alpha.-ethinyl estradiol and the amount of substance exhibiting progestin activity per unit dose ranges from 0 to an amount which exhibits a progestin activity equivalent to about 1 mg of norethindrone.

2. A contraceptive preparation according to claim 1, wherein all of said daily unit doses contain a uniform amount of said substance exhibiting estrogen activity.

3. A contraceptive preparation according to claim 1, wherein the daily unit doses of said estrogen dominant phases are free of substance exhibiting progestin activity.

4. A contraceptive preparation according to claim 1, wherein said substance exhibiting estrogen activity is selected from the group consisting of 17.alpha.-ethinyl estradiol, 17.beta.-estradiol, 17.beta.-estradiol valerate, conjugated equine estrogens, piperazine estrone sulfate, and estropipate, and said substance exhibiting progestin activity is selected from the group consisting of norethindrone, desogestrel, levo-norgestrel, norgestimate, progesterone, medroxy-progesterone acetate, gestodene, and cyproterone acetate.

5. A contraceptive preparation according to claim 1, wherein said daily unit doses are in a form selected from the group consisting of orally administrable form, transdermally administrable form, and buccally administrable form.

6. A contraceptive preparation according to claim 1, comprising a series of consecutive daily unit doses arranged in estrogen dominant phases of two daily unit doses each alternating with progestin dominant phases of two daily unit doses each.

7. A contraceptive preparation according to claim 1, comprising a series of consecutive daily unit doses arranged in estrogen dominant phases of three daily unit doses each alternating with progestin dominant phases of three daily unit doses each.

8. A contraceptive preparation according to claim 1, wherein each of said daily unit doses contains an amount of substance exhibiting estrogen activity which exhibits an estrogen activity equivalent to from 0.02 to 0.05 mg of 17.alpha.-ethinyl estradiol, and an amount of substance exhibiting progestin activity ranging from 0 to an amount which exhibits a progestin activity equivalent to 1 mg norethindrone.

9. A contraceptive preparation according to claim 8, wherein each of said daily unit doses contains an amount of substance exhibiting progestin activity which exhibits a progestin activity equivalent to at least 0.15 mg norethindrone.

10. A contraceptive preparation according to claim 8, wherein three unit doses of 0.035 mg of 17.alpha.-ethinyl estradiol and 0.35 mg of norethindrone are alternated with three unit doses of 0.035 mg of 17.alpha.-ethinyl estradiol and 0.5 mg of norethindrone.

11. A contraceptive preparation according to claim 8, wherein each estrogen dominant phase consists of three daily unit doses each containing 0.035 17.alpha.-ethinyl estradiol and 0.035 mg of norgestimate and each progestin dominant phase consists of three daily unit doses each containing 0.035 mg of 17.alpha.-ethinyl estradiol and 0.05 mg of norgestimate.

12. A contraceptive preparation according to claim 1, for administration to a female of childbearing potential, comprising repeating cycles of a contraceptive regimen, wherein each cycle comprises a total of twenty-eight consecutive daily unit doses, from twenty-one to twenty-four of which exhibit hormone activity and are arranged in alternating estrogen dominant phases and progestin dominant phases, each phase consisting of from one to four consecutive daily unit doses, and each cycle ending with from four to seven hormone activity-free daily unit doses.

13. A contraceptive package containing at least one cycle of a contraceptive regimen for administration to a female of childbearing capability wherein each cycle comprises a series of twenty to thirty-five consecutive daily unit dosages, arranged in a fixed sequence corresponding to an intended order of administration consisting of alternating estrogen dominant phases and progestin dominant phases, each phase consisting of from two to four consecutive daily unit doses, wherein the daily unit doses of said estrogen dominant phases contain i) an amount of a substance exhibiting estrogen activity or ii) an amount of a substance exhibiting estrogen activity and an amount of a substance exhibiting progestin activity, and the daily unit doses of said progestin dominant phases contain an amount of a substance exhibiting estrogen activity and an amount of a substance exhibiting progestin activity; wherein the amount of said substance exhibiting progestin activity is alternately increased in the progestin dominant phases to provide daily unit doses exhibiting progestin dominant activity and decreased in the estrogen dominant phases to provide daily unit doses exhibiting estrogen dominant activity, and wherein the amount of substance exhibiting estrogen activity per unit dose exhibits an estrogen activity equivalent to from about 0.02 to about 0.05 mg of 17.alpha.-ethinyl estradiol and the amount of substance exhibiting progestin activity per unit dose ranges from 0 to an amount which exhibits a progestin activity equivalent to about 1 mg of norethindrone.

14. A contraceptive package according to claim 13, wherein all of said daily unit doses contain a uniform amount of said substance exhibiting estrogen activity.

15. A contraceptive package according to claim 13, wherein the daily unit doses of said estrogen dominant phases are free of substance exhibiting progestin activity.

16. A contraceptive package according to claim 13, wherein said substance exhibiting estrogen activity is selected from the group consisting of 17.alpha.-ethinyl estradiol, 17.beta.-estradiol, 17.beta.-estradiol valerate, conjugated equine estrogens, piperazine estrone sulfate, and estropipate, and said substance exhibiting progestin activity is selected from the group consisting of norethindrone, desogestrel, levo-norgestrel, norgestimate, progesterone, gestodene, cyproterone acetate and medroxy-progesterone acetate.

17. A contraceptive package according to claim 13, wherein said daily unit doses are in a form selected from the group consisting of orally administrable form, transdermally administrable form, and buccally administrable form.

18. A contraceptive package according to claim 13, containing a series of consecutive daily unit doses arranged in estrogen dominant phases of two daily unit doses each alternating with progestin dominant phases of two daily unit doses each.

19. A contraceptive package according to claim 13, containing a series of consecutive daily unit doses arranged in estrogen dominant phases of three daily unit doses each alternating with progestin dominant phases of three daily unit doses each.

20. A contraceptive package according to claim 13, containing a contraceptive preparation, wherein each of said daily unit doses contains an amount of substance exhibiting estrogen activity equivalent to from 0.02 to 0.05 mg of 17.alpha.-ethinyl estradiol, and an amount of substance exhibiting progestin activity ranging from 0 to an amount which exhibits a progestin activity equivalent to 1 mg norethindrone.

21. A contraceptive package according to claim 20, wherein said substance exhibiting estrogen activity is 17.alpha.-ethinyl estradiol, and said substance exhibiting progestin activity is selected from the group consisting of norethindrone, desogestrel, levo-norgestrel, norgestimate, progesterone, medroxy-progesterone acetate, and gestodene.

22. A contraceptive package as claimed in claim 20, comprising repeating cycles of a contraceptive regimen, wherein each cycle comprises a total of twenty-eight consecutive daily unit doses, from twenty-one to twenty-four of which exhibit hormone activity and are arranged in alternating estrogen dominant phases and progestin dominant phases, each phase consisting of from one to four consecutive daily unit doses, and each cycle ending with from four to seven hormone activity-free daily unit doses.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc